SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

210

Participants

Timeline

Start Date

June 6, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

SC1011

Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.

DRUG

Placebo comparator

Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.

Trial Locations (1)

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Guangzhou JOYO Pharma Co., Ltd

INDUSTRY